Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease
(2020) In Neurobiology of Aging 95. p.143-153- Abstract
Cerebrospinal fluid (CSF) neurofilament light (NfL) concentration has reproducibly been shown to reflect neurodegeneration in brain disorders, including Alzheimer's disease (AD). NfL concentration in blood correlates with the corresponding CSF levels, but few studies have directly compared the reliability of these 2 markers in sporadic AD. Herein, we measured plasma and CSF concentrations of NfL in 478 cognitively unimpaired (CU) subjects, 227 patients with mild cognitive impairment, and 113 patients with AD dementia. We found that the concentration of NfL in CSF, but not in plasma, was increased in response to Aβ pathology in CU subjects. Both CSF and plasma NfL concentrations were increased in patients with mild cognitive impairment... (More)
Cerebrospinal fluid (CSF) neurofilament light (NfL) concentration has reproducibly been shown to reflect neurodegeneration in brain disorders, including Alzheimer's disease (AD). NfL concentration in blood correlates with the corresponding CSF levels, but few studies have directly compared the reliability of these 2 markers in sporadic AD. Herein, we measured plasma and CSF concentrations of NfL in 478 cognitively unimpaired (CU) subjects, 227 patients with mild cognitive impairment, and 113 patients with AD dementia. We found that the concentration of NfL in CSF, but not in plasma, was increased in response to Aβ pathology in CU subjects. Both CSF and plasma NfL concentrations were increased in patients with mild cognitive impairment and AD dementia. Furthermore, only NfL in CSF was associated with reduced white matter microstructure in CU subjects. Finally, in a transgenic mouse model of AD, CSF NfL increased before serum NfL in response to the development of Aβ pathology. In conclusion, NfL in CSF may be a more reliable biomarker of neurodegeneration than NfL in blood in preclinical sporadic AD.
(Less)
- author
- Andersson, Emelie
LU
; Janelidze, Shorena LU ; Lampinen, Björn LU ; Nilsson, Markus LU ; Leuzy, Antoine LU ; Stomrud, Erik LU
; Blennow, Kaj LU ; Zetterberg, Henrik LU and Hansson, Oskar LU
- organization
- publishing date
- 2020
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, Biomarker, Blood, Cerebrospinal fluid, Imaging, Neurofilament light
- in
- Neurobiology of Aging
- volume
- 95
- pages
- 11 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:85089429751
- pmid:32810755
- ISSN
- 0197-4580
- DOI
- 10.1016/j.neurobiolaging.2020.07.018
- language
- English
- LU publication?
- yes
- id
- 05052e16-b721-45d9-8010-7b563ef275c6
- date added to LUP
- 2020-08-24 09:48:29
- date last changed
- 2024-05-15 16:34:39
@article{05052e16-b721-45d9-8010-7b563ef275c6, abstract = {{<p>Cerebrospinal fluid (CSF) neurofilament light (NfL) concentration has reproducibly been shown to reflect neurodegeneration in brain disorders, including Alzheimer's disease (AD). NfL concentration in blood correlates with the corresponding CSF levels, but few studies have directly compared the reliability of these 2 markers in sporadic AD. Herein, we measured plasma and CSF concentrations of NfL in 478 cognitively unimpaired (CU) subjects, 227 patients with mild cognitive impairment, and 113 patients with AD dementia. We found that the concentration of NfL in CSF, but not in plasma, was increased in response to Aβ pathology in CU subjects. Both CSF and plasma NfL concentrations were increased in patients with mild cognitive impairment and AD dementia. Furthermore, only NfL in CSF was associated with reduced white matter microstructure in CU subjects. Finally, in a transgenic mouse model of AD, CSF NfL increased before serum NfL in response to the development of Aβ pathology. In conclusion, NfL in CSF may be a more reliable biomarker of neurodegeneration than NfL in blood in preclinical sporadic AD.</p>}}, author = {{Andersson, Emelie and Janelidze, Shorena and Lampinen, Björn and Nilsson, Markus and Leuzy, Antoine and Stomrud, Erik and Blennow, Kaj and Zetterberg, Henrik and Hansson, Oskar}}, issn = {{0197-4580}}, keywords = {{Alzheimer's disease; Biomarker; Blood; Cerebrospinal fluid; Imaging; Neurofilament light}}, language = {{eng}}, pages = {{143--153}}, publisher = {{Elsevier}}, series = {{Neurobiology of Aging}}, title = {{Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease}}, url = {{http://dx.doi.org/10.1016/j.neurobiolaging.2020.07.018}}, doi = {{10.1016/j.neurobiolaging.2020.07.018}}, volume = {{95}}, year = {{2020}}, }